SCHEMBL22762267

SCHEMBL22762267

CN(C)C(C=O)c1csc(N[S+]([O-])C2CC2)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21076840 0.72 POLB (0.36) —
SCHEMBL21076983 0.71 GCK (0.32) —
SCHEMBL22762493 0.68 ATAD2 (0.34) —
SCHEMBL21077072 0.64 ALDH1A1 (0.50) —
SCHEMBL21076846 0.64 ALDH1A1 (0.44) —
SCHEMBL21077047 0.63 CTPS1 (0.52) —
SCHEMBL12894440 0.52 CCR4 (0.46) —
SCHEMBL16472953 0.52 ALOX5 (0.41) —
SCHEMBL22838132 0.51 CCR4 (0.49) —
SCHEMBL21990942 0.51 GSK3B (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020245665-A1 N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES STEP PHARMA S.A.S. (FR) 2020-12-10 — — WO disclosed
Send feedback